ASCRS 2024: Transforming how we think about IOL calculation with Light Adjustable Lens technology

News
Video

Dr Neda Nikpoor discusses Light Adjustable Lenses and the implications for clinicians at ASCRS 2024

Neda Nikpoor, MD, spoke to Ophthalmology Times about her presentation on the Light Adjustable Lens during an ASCRS symposia on IOL calculations.

Video Transcript

Editor's note - The following transcript has been lightly edited for clarity.

Neda Nikpoor, MD: Hi, my name is Neda Nikpoor. I am a private practice doctor—a cornea, cataract, and refractive surgeon in Honolulu, Hawaii. I have the pleasure of giving a talk in the IOL calculation section on Light Adjustable Lenses. So, how easy of a talk could I have gotten because honestly everything else in that session is all about how to do all these complex calculations, all the formulas. And my part is simple, because with the Light Adjustable Lens [RxSight Inc.], you literally just need to be within two diopters of sphere and three diopters of cylinder, and you can hit your target. But obviously, there's a little bit more to it than that.

So some of the data that's actually really pretty powerful around Light Adjustable Lens is that in the phase 4 data, well over 90% of eyes were within a half diopter for mean residual spherical equivalent, as well as residual astigmatism. And that really low amount of residual refractive error leads to better visual outcomes. And so patients had high rates close to 90% of seeing uncorrected 20/20 at distance, and over 90% of patients binocularly would see J1 or better at near.

The other thing that's really exciting with Light Adjustable Lens technology is we now have LAL+ [Light Adjustable Lens+] and LAL+ as most of you know has a little bit more extended depth of focus [EDOF] than the original LAL, which also has some EDOF built into it. And that translates into better range of vision for patients.

Now the really nice thing is we always say there's no free lunch. But honestly with this it kind of seems like there is. The only sacrifice that we've seen in distance vision across the study was 1 letter, and the improvement in near was significant. So the monocular distance corrected near mean in patients is 20/40, at near, which is really quite incredible for a monofocal lens that has some EDOF. The rates of glare, halo, dysphotopsia, or anything like that are still very, very, very low and no different from the traditional LAL.

So you can rest assured that with this lens, honestly, it seems based on the data that patients do get excellent distance and near vision and have great binocular vision and over 80% of patients in the study actually chose blended vision. So that makes IOL calculation a lot easier I think.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.